Establish your trading edge with a set of smart tools for serious trades.
Upgrade Account
stock
Adaptimmune Therapeutics Plc
NASDAQ | ADAP
0.30
USD
+0.055 (+22.00%)
AT CLOSE (AS OF Apr 2, 2025)
$64M
MARKET CAP
-
P/E Ratio
-0.3
EPS
$1.5
52 Week High
$0.2
52 Week Low
LIFE SCIENCES
Sector
ADAP Chart
1D
Area
Trade Smarter
Take control of your trading journey with a set of smart tools for serious trades
ADAP Technicals
ADAP Earnings
Yearly Income Statement (As of Dec 31, 2023)
| Field | Value (USD) |
|---|---|
| Gross Profit | -$15M |
| Total Revenue | $60M |
| Cost Of Revenue | $75M |
| Costof Goods And Services Sold | $9.9M |
| Operating Income | -$140M |
| Selling General And Administrative | $74M |
| Research And Development | $127M |
| Operating Expenses | $202M |
| Investment Income Net | $2M |
| Net Interest Income | $6M |
| Interest Income | $6M |
| Interest Expense | - |
| Non Interest Income | $60M |
| Other Non Operating Income | -$807K |
| Depreciation | $9.5M |
| Depreciation And Amortization | $366K |
| Income Before Tax | -$113M |
| Income Tax Expense | $1.3M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$114M |
| Comprehensive Income Net Of Tax | -$117M |
| Ebit | -$140M |
| Ebitda | -$139M |
| Net Income | -$114M |
Revenue & Profitability
Earnings Performance
ADAP Financials
yearly Balance Sheet (As of Dec 31, 2023)
| Field | Value (USD) |
|---|---|
| Total Assets | $283M |
| Total Current Assets | $208M |
| Cash And Cash Equivalents At Carrying Value | $144M |
| Cash And Short Term Investments | $147M |
| Inventory | $1.3M |
| Current Net Receivables | $821K |
| Total Non Current Assets | $75M |
| Property Plant Equipment | $51M |
| Accumulated Depreciation Amortization Ppe | $46M |
| Intangible Assets | $330K |
| Intangible Assets Excluding Goodwill | $330K |
| Goodwill | - |
| Investments | $5.9M |
| Long Term Investments | - |
| Short Term Investments | $2.9M |
| Other Current Assets | $2.4M |
| Other Non Current Assets | - |
| Total Liabilities | $243M |
| Total Current Liabilities | $73M |
| Current Accounts Payable | $8.1M |
| Deferred Revenue | $356M |
| Current Debt | - |
| Short Term Debt | $5.4M |
| Total Non Current Liabilities | $170M |
| Capital Lease Obligations | $25M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $25M |
| Other Current Liabilities | $51K |
| Other Non Current Liabilities | $1.4M |
| Total Shareholder Equity | $40M |
| Treasury Stock | - |
| Retained Earnings | -$1B |
| Common Stock | $1.9M |
| Common Stock Shares Outstanding | $1.4B |
yearly Cash Flow (As of Dec 31, 2023)
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$141M |
| Payments For Operating Activities | $9.9M |
| Proceeds From Operating Activities | $8.7M |
| Change In Operating Liabilities | -$24M |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $9.8M |
| Capital Expenditures | $4.9M |
| Change In Receivables | - |
| Change In Inventory | -$1 |
| Profit Loss | -$114M |
| Cashflow From Investment | $177M |
| Cashflow From Financing | $880K |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | $624K |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $880K |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$114M |
yearly Income Statement (As of Dec 31, 2023)
| Field | Value (USD) |
|---|---|
| Gross Profit | -$15M |
| Total Revenue | $60M |
| Cost Of Revenue | $75M |
| Costof Goods And Services Sold | $9.9M |
| Operating Income | -$140M |
| Selling General And Administrative | $74M |
| Research And Development | $127M |
| Operating Expenses | $202M |
| Investment Income Net | $2M |
| Net Interest Income | $6M |
| Interest Income | $6M |
| Interest Expense | - |
| Non Interest Income | $60M |
| Other Non Operating Income | -$807K |
| Depreciation | $9.5M |
| Depreciation And Amortization | $366K |
| Income Before Tax | -$113M |
| Income Tax Expense | $1.3M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$114M |
| Comprehensive Income Net Of Tax | -$117M |
| Ebit | -$140M |
| Ebitda | -$139M |
| Net Income | -$114M |
ADAP Profile
Adaptimmune Therapeutics Plc Profile
Sector: LIFE SCIENCES
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to solid tumor patients in the United States and the United Kingdom. The company is headquartered in Abingdon, the United Kingdom.
Discover more tools and features to empower your trading
Explore FeaturesQuotes and other market data may be delayed by 15 minutes or more. Financial data is provided by financial exchanges and other content providers and may be delayed as specified by financial exchanges or other data providers. AfterPullback does not verify any data and disclaims any obligation to do so. The information contained on this website is not intended as, and shall not be understood as, financial advice. The website does not operated by attorney, accountant or financial advisor and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation. Nothing available on or through this website should be understood as a recommendation that you should not consult with a financial professional to address your particular information.